J Drugs Dermatol
-
Lidocaine hydrochloride is the most commonly used anesthetic agent in dermatology. Despite its widespread and frequent use, adverse reactions to lidocaine are uncommon. ⋯ Immunologically mediated allergic reactions are thought to account for only 1% of these adverse reactions. We report an extremely rare case of a true type I hypersensitivity allergy to lidocaine hydrochloride.
-
Topical anesthetic agents are frequently used by dermatologists to decrease the pain associated with a variety of cutaneous procedures, including laser surgery, soft tissue augmentation, and other cosmetic surgical treatments. These lidocaine-containing creams play an integral role in the cosmetic dermatology office by providing patient comfort with minimal side effects. This review of topical lidocaine preparations should aid practitioners in the selection of an appropriate topical anesthetic, taking into consideration its onset and duration of action and potential side effects.
-
Lentigo maligna (LM) is an in situ melanoma that occurs in sun-damaged skin on the head and neck of elderly patients. Surgical excision is the treatment of choice for LM. However, surgical options may be limited by the location of LM in cosmetically sensitive areas. ⋯ Histologic clearance of the lentigo maligna was evident in skin biopsies. Imiquimod 5% cream appears effective in the treatment of lentigo maligna. We describe the treatment of a patient with facial LM with imiquimod 5% cream.
-
Clinical Trial
Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Nodular basal cell carcinoma (nBCC) is the most common cutaneous malignancy and studies assessing the use of topical imiquimod 5% cream as a monotherapy in the treatment of nBCC have resulted in less than optimal clearance rates. ⋯ Imiquimod 5% cream appears to be an effective treatment method for nodular basal cell carcinoma if combined with curettage prior to application.
-
Case Reports
Case reports: red scrotal syndrome: a localized phenotypical expression of erythromelalgia.
We report a case of red scrotal syndrome responding to oral gabapentin, a neuropathic mediator that is commonly used in the treatment of primary erythromelalgia. The positive response to oral gabapentin and the resemblance of these 2 conditions supports that red scrotal syndrome is a phenotypical expression of localized primary erythromelalgia.